Drug Trial Radar · NCT06417814
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
768
Actual
Start
Oct 4, 2024
Primary completion
Jan 11, 2027
Study completion Sep 27, 2028
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Daiichi Sankyo
- First posted
- May 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the effect of Dato-DXd in combination with osimertinib or Dato-DXd monotherapy versus platinum-based doublet chemotherapy in terms of progression-free survival (PFS).
Conditions
- Metastatic Non-small Cell Lung Cancer
Interventions
Dato-DXdDrug
Dato-DXd will be administered as IV infusion.
OsimertinibDrug
Osimertinib will be administered orally.
PemetrexedDrug
Pemetrexed will be administered as IV infusion.
CarboplatinDrug
Carboplatin will be administered as IV infusion.
CisplatinDrug
Cisplatin will be administered as IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free Survival (PFS)Time frame: Up to 2.5 years
Locations
211 sites in 24 countries. Site status is shown where the registry gives one.
Research Site
Fayetteville, Arkansas
Research Site
Fountain Valley, California
Research Site
San Diego, California
Research Site
Jacksonville, Florida
Research Site
Kansas City, Missouri
Research Site
New York, New York
Research Site
Maumee, Ohio
Research Site
Pittsburgh, Pennsylvania
Research Site
Nashville, Tennessee
Research Site
Fitzroy, Australia
Research Site
Heidelberg, Australia
Research Site
Kogarah, Australia
Research Site
Liverpool, Australia
Research Site
Nedlands, Australia
Research Site
St Leonards, Australia
Research Site
Westmead, Australia
Research Site
Woolloongabba, Australia
Research Site
Charleroi, Belgium
Research Site
Edegem, Belgium
Research Site
Ghent, Belgium
Research Site
Hasselt, Belgium
Research Site
Jette, Belgium
Research Site
Namur, Belgium
Research Site
Roeselare, Belgium
Research Site
Barretos, Brazil
Research Site
Betim, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
São Paulo, Brazil
Research Site
Brampton, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Québec, Quebec, Canada
Research Site
Baoding, China
Research Site
Beijing, China
Research Site
Beijing, China
Showing 40 of 211 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.